Opexa Therapeutics Inc. (NASDAQ:OPXA) received a $18.00 target price from equities research analysts at Maxim Group in a report released on Tuesday. The firm currently has a a “buy” rating on the biopharmaceutical company’s stock. Maxim Group’s target price points to a potential upside of 423.26% from the stock’s previous close.

Other equities research analysts also recently issued reports about the stock. Aegis boosted their price target on shares of Opexa Therapeutics to $11.00 and gave the stock a “buy” rating in a research note on Monday, July 18th. Chardan Capital reissued a “buy” rating and set a $6.00 price target on shares of Opexa Therapeutics in a research note on Sunday, July 3rd. Finally, Zacks Investment Research downgraded shares of Opexa Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 20th.

Opexa Therapeutics (NASDAQ:OPXA) traded down 6.6831% on Tuesday, hitting $3.2101. 96,448 shares of the stock were exchanged. Opexa Therapeutics has a one year low of $1.69 and a one year high of $5.10. The company has a 50 day moving average of $4.12 and a 200 day moving average of $3.28. The stock’s market capitalization is $22.63 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/maxim-group-analysts-give-opexa-therapeutics-inc-opxa-a-18-00-price-target.html

Opexa Therapeutics (NASDAQ:OPXA) last posted its quarterly earnings results on Thursday, August 11th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.23) by $0.07. Opexa Therapeutics had a negative return on equity of 109.48% and a negative net margin of 324.97%. During the same quarter in the prior year, the company earned ($0.56) EPS. On average, equities research analysts forecast that Opexa Therapeutics will post ($1.12) earnings per share for the current fiscal year.

An institutional investor recently raised its position in Opexa Therapeutics stock. Renaissance Technologies LLC raised its stake in Opexa Therapeutics Inc. (NASDAQ:OPXA) by 9.5% during the first quarter, according to its most recent disclosure with the SEC. The firm owned 148,189 shares of the biopharmaceutical company’s stock after buying an additional 12,900 shares during the period. Renaissance Technologies LLC owned approximately 2.16% of Opexa Therapeutics worth $344,000 as of its most recent SEC filing. 6.40% of the stock is currently owned by institutional investors.

Opexa Therapeutics Company Profile

Opexa Therapeutics, Inc (Opexa) is a biopharmaceutical company. The Company is engaged in the development of a personalized immunotherapy with the potential to treat various illnesses, including multiple sclerosis (MS), as well as other autoimmune diseases, such as neuromyelitis optica (NMO). These therapies are based on its T-cell technology.

5 Day Chart for NASDAQ:OPXA

Receive News & Ratings for Opexa Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opexa Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.